This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Ongoing research is needed to fully understand their risks, especially for long-term and higher-dose users. However, many ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...